PROBLEM Allergic rhinitis represents a global public health problem. In Mexico, the prevalence ranges from 10 to 30%. Immunotherapy is the treatment of choice, however, the time it takes to start the therapeutic response is prolonged, on average 6 months, which results in poor adhesion ranging from 13% to 89%. So you need to find strategies to accelerate the therapeutic response. It is known that the administration of vitamin D immunotherapy in allergic diseases, decreases symptoms as well as the use of drugs associated with increased IgG4, IL10, TGF-b and T reg cells. Also inhibits mediated immune reactions TH1 and TH17 cells the, reduces allergic inflammation and cytokine expression mediated by TH2 cells, although it is unknown whether the start time decreases action of specific immunotherapy in children with allergic rhinitis. It is known that adding vitamin D to conventional treatment of patients with atopic dermatitis decreases the severity of symptoms 40% faster (3 months) than with conventional treatment (5 months). Therefore we propose that the administration of vitamin D more immunotherapy adjuvant, may decrease the time of onset of immunotherapy at least 40% and therefore its effectiveness is improved by a better adherence.